<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="24938">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01746914</url>
  </required_header>
  <id_info>
    <org_study_id>201212</org_study_id>
    <nct_id>NCT01746914</nct_id>
  </id_info>
  <brief_title>Morphofunctional Lung Analysis by PET and CT After Lung Transplantation</brief_title>
  <official_title>Morphofunctional Lung Analysis by Positron Emission Tomography and Computed Tomography After Lung Transplantation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Policlinico Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Policlinico Hospital</source>
  <oversight_info>
    <authority>Italy: Ministry of Health</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      72 hours after lung transplantation, patients undergo a positron emission tomography (PET)
      scan and a computed tomography (CT) scan in order to analyse lung function and morphology.

      Aim of the study is to analyse complications onset (in particular primary graft
      dysfunction), and evaluate 90 days mortality after lung transplantation.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Pulmonary transplantation is considered as a lifesaving procedure in end-stage pulmonary
      disease. However morbidity and mortality after lung transplantation are still significant.

      Primary graft dysfunction (PGD) is the main cause of early death. PGD is similar to acute
      lung injury (ALI)/ acute respiratory distress syndrome (ARDS): oxygenation is compromised,
      pulmonary compliance is decreased, chest Rx shows several infiltrates, and alveolar damage
      is present.

      25% of patients develops PGD within 72 hours from transplantation and 30 days mortality is
      eight times higher in patients who develop PGD.

      72 hours after lung transplantation, patients, whose clinical condition allow to bring them
      to nuclear medicine department, will undergo pulmonary computed tomography (CT) to study
      lung morphology and measure lung recruitability and positron emission tomography (PET) to
      study lung functionality and estimate lung inflammation.

      Aim of this study is to investigate the onset of PGD and other complications and to
      determine 72 hours and 90 days mortality after lung transplantation.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>January 2013</start_date>
  <completion_date type="Anticipated">January 2016</completion_date>
  <primary_completion_date type="Anticipated">July 2014</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Observational</study_type>
  <study_design>Observational Model: Cohort, Time Perspective: Prospective</study_design>
  <primary_outcome>
    <measure>Number of patients alive</measure>
    <time_frame>up to 90 days from transplantation</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>incidence of complications other than primary graft dysfunction</measure>
    <time_frame>72 hours and 90 days</time_frame>
    <safety_issue>Yes</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>incidence of primary graft dysfunction</measure>
    <time_frame>72 hours and 90 days after transplantation</time_frame>
    <safety_issue>Yes</safety_issue>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Disorder Related to Lung Transplantation</condition>
  <arm_group>
    <arm_group_label>Lung transplantated patients</arm_group_label>
    <description>Patients undergone lung transplantation</description>
  </arm_group>
  <eligibility>
    <study_pop>
      <textblock>
        Lung Transplantated patients
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  lung transplantation

          -  â‰¥ 18 years

        Exclusion Criteria:

          -  &lt; 18 years

          -  patient' s clinical conditions not allowing patient transport from ICU to Nuclear
             Medicine Unit
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Davide Chiumello, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Policlinico Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Franco Valenza, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Policlinico Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Davide Chiumello, MD</last_name>
    <phone>+390255033237</phone>
    <email>chiumello@libero.it</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Franco Valenza, MD</last_name>
    <phone>+390255033232</phone>
    <email>franco.valenza@unimi.it</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico</name>
      <address>
        <city>Milano</city>
        <state>Milan</state>
        <zip>20122</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Davide Chiumello, MD</last_name>
      <phone>+390255033237</phone>
      <email>chiumello@libero.it</email>
    </contact>
    <contact_backup>
      <last_name>Franco Valenza, MD</last_name>
      <phone>+390255033232</phone>
      <email>franco.valenza@unimi.it</email>
    </contact_backup>
    <investigator>
      <last_name>Davide Chiumello, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Franco Valenza, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Italy</country>
  </location_countries>
  <verification_date>June 2013</verification_date>
  <lastchanged_date>June 12, 2013</lastchanged_date>
  <firstreceived_date>December 7, 2012</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Policlinico Hospital</investigator_affiliation>
    <investigator_full_name>Davide Chiumello</investigator_full_name>
    <investigator_title>MD</investigator_title>
  </responsible_party>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
